NASDAQ · Biotechnology

Mesoblast Limited (MESO) Stock

$18.24 +8.96% NASDAQ: MESO Healthcare

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland.

Valuation

MetricValue
Price$18.24
Market Cap$2.36B
P/E Ratio-25.86
P/B Ratio4.28
P/S Ratio37.63
EPS (TTM)$-0.84
52-Week High$21.50
52-Week Low$11.05
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-16.10%
ROA-12.06%
ROCE-22.29%
Gross Margin-53.34%
Operating Margin-223.08%
Net Margin-144.33%
Debt/Equity0.24
Current Ratio1.58

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.0M$10.0M$8.0M$6.0M$17.0M
Operating Profit$-109.0M$-81.0M$-69.0M$-84.0M$-62.0M
Net Profit$-99.0M$-91.0M$-82.0M$-88.0M$-102.0M
EPS$-1.60$-1.30$-0.98$-0.89$-0.84
Op Margin-1463.2%-789.1%-923.7%-1425.7%-363.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$745.0M$662.0M$669.0M$669.0M$785.0M
Total Liabilities$163.0M$165.0M$168.0M$189.0M$187.0M
Cash$137.0M$60.0M$71.0M$63.0M$161.0M
Borrowings$105.0M$107.0M$116.0M$119.0M$128.0M

Latest News

Mesoblast Completes Treatment Target in Phase 3 Back Pain Trial MT Newswires · Jul 14, 2026 Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain GlobeNewswire · Jul 14, 2026 Sector Update: Healthcare Stocks Advance Premarket Friday MT Newswires · Jul 10, 2026 Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Amid Renewed US-Iran Tensions Ahead of Q2 Earnings Season MT Newswires · Jul 10, 2026 Sector Update: Healthcare MT Newswires · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-107.0M$-66.0M$-63.0M$-48.0M$-50.0M
Investing Cash Flow$-3.0M$-1.0M$0$0$-1.0M
Financing Cash Flow$5.0M$-4.0M$-11.0M$-12.0M$-4.0M
Net Cash Flow$8.0M$-76.0M$11.0M$-8.0M$99.0M
Free Cash Flow$-108.0M$-66.0M$-64.0M$-49.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.14
EV / EBITDA-38.33
FCF Yield-2.13%
Quick Ratio1.41
Interest Coverage-2.70
Return 1Y8.09%
Return 3Y68.74%
Return 5Y12.26%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
COGT $42.27 -1.33% -34.70 $7.22B 0.00%
EWTX $43.52 -2.03% -14.63 $4.68B 0.00%
GLPGGalapagos N.V. $27.98 +1.71% 3.57 $1.84B 0.00%
GPCRStructure Therapeutics Inc. $53.36 -3.23% -20.21 $3.07B 0.00%
IBRXImmunityBio, Inc. $7.00 -1.48% -8.32 $7.33B 0.00%

About Mesoblast Limited

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.

Mesoblast Limited is headquartered in AU.

Mesoblast Limited (MESO) stock trades at $18.24 with a market capitalization of $2.36B. The stock is valued at a price-to-earnings (P/E) ratio of -25.86, price-to-book of 4.28, price-to-sales of 37.63. Over the past 52 weeks the stock has ranged between $11.05 and $21.50, and currently trades 15.2% below its 52-week high.

On profitability, Mesoblast Limited generates a return on equity (ROE) of -16.10%, return on capital employed of -22.29%, an operating margin of -223.08%, a net profit margin of -144.33%.

Official website: www.mesoblast.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides